Ranoflip-500 ER Tablets

Ranoflip-500 ER – Ranolazine 500 mg Sustained Release Tablets

Ranoflip-500 ER contains Ranolazine 500 mg in a sustained release tablet formulation. Ranolazine is an antianginal medicine used for the treatment of chronic angina. It is designed for long-term management of recurring anginal symptoms and may be used alongside other medicines prescribed for cardiovascular conditions.

What Is Ranoflip-500 ER Used For?

Ranoflip-500 ER is used for the treatment of chronic angina, a condition characterized by recurring chest discomfort or pain associated with inadequate oxygen supply to the heart muscle.

Ranolazine may be prescribed when ongoing antianginal therapy is required to help manage chronic anginal symptoms. It can be used with other cardiovascular medicines according to the patient's individual treatment plan.

Uses of Ranoflip-500 ER

Ranoflip-500 ER may be used for:

• Treatment of chronic angina

• Long-term management of recurring anginal symptoms

• Management of chronic stable angina as prescribed by a healthcare professional

• Adjunctive antianginal therapy in patients requiring additional symptom control

• Cardiovascular management where an appropriate antianginal medicine is required

How Does Ranolazine Work?

Ranolazine is an antianginal medicine with a mechanism that differs from conventional medicines used primarily to reduce heart rate or blood pressure.

It acts on cellular processes involved in myocardial energy metabolism and helps improve the efficiency of oxygen utilization by the heart muscle under conditions of ischemia.

This pharmacological action can help reduce the frequency of anginal symptoms in patients with chronic angina.

Ranolazine for Chronic Angina

Chronic angina is commonly associated with coronary artery disease and may present as recurring chest discomfort during physical activity or emotional stress.

The underlying problem involves an imbalance between the oxygen demand of the heart and the oxygen supply available to the cardiac muscle.

Ranolazine is used as part of chronic angina management to help reduce recurring symptoms.

It is particularly relevant when patients continue to experience anginal symptoms despite other antianginal treatment or when additional therapy is considered appropriate.

Role in Cardiovascular Therapy

Ranolazine is an established antianginal medicine used in cardiovascular practice.

It can be prescribed alongside other medicines used for cardiovascular conditions, including beta-blockers, nitrates and calcium channel blockers, depending on the patient's clinical requirements.

The choice of combination therapy should be determined by a qualified healthcare professional after considering the patient's cardiovascular condition, existing medicines and overall treatment response.

Ranolazine and Blood Pressure

Ranolazine is primarily an antianginal medicine rather than a conventional blood-pressure-lowering medicine.

Its principal therapeutic role is the management of chronic angina and recurring anginal symptoms.

Therefore, it should not be positioned as a primary medicine for hypertension when describing its therapeutic application.

Ranolazine and Heart Rate

Ranolazine provides an antianginal effect through a mechanism that is different from medicines that primarily reduce heart rate or blood pressure.

This makes its pharmacological profile relevant in patients with chronic angina where additional symptom management is required.

Product Information

Brand Name: Ranoflip-500 ER

Composition: Ranolazine Sustained Release Tablets 500 mg

Active Ingredient: Ranolazine

Strength: 500 mg

Dosage Form: Sustained Release Tablets

Route of Administration: Oral

Therapeutic Segment: Cardiology / Antianginal Therapy

Primary Indication: Chronic Angina

Packing: 10 x 10 Tablets

Key Product Features

• Ranolazine 500 mg formulation

• Sustained release tablet dosage form

• Antianginal medicine

• Used for chronic angina management

• Suitable for long-term anginal symptom management when prescribed appropriately

• Can be used as part of combination cardiovascular therapy

• Oral tablet formulation

• 10 x 10 tablet packing

Important Information

Ranoflip-500 ER is a prescription medicine and should be used under the supervision of a qualified healthcare professional.

The appropriate dose and treatment duration depend on the patient's medical condition, response to treatment, other medicines and individual clinical factors.

The sustained release tablets should be taken exactly as prescribed. The tablets should generally be swallowed whole and should not be crushed, broken or chewed unless specifically instructed by a healthcare professional.

Ranolazine may interact with certain medicines, particularly medicines that affect CYP3A metabolism. Patients should inform their healthcare professional about all prescription medicines, over-the-counter medicines and supplements they are taking.

Ranolazine can prolong the QT interval in some patients. Appropriate medical evaluation is important in patients with known QT prolongation or other relevant cardiac risk factors.

Patients with kidney or liver problems should inform their healthcare professional before treatment because additional precautions or treatment adjustments may be required.

Storage

Store the product according to the storage conditions specified on the approved product label.

Keep the tablets in their original packaging and away from children.

Product Summary

Ranoflip-500 ER contains Ranolazine 500 mg in a sustained release tablet formulation for oral administration.

Ranolazine is primarily used as an antianginal medicine for the treatment of chronic angina. It supports long-term management of recurring anginal symptoms and may be incorporated into a broader cardiovascular treatment plan when clinically appropriate.

Its sustained release formulation provides a convenient oral dosage form for patients requiring prescribed Ranolazine therapy.